Common Side Effects Reported in Kadcyla Trials
Kadcyla (ado-trastuzumab emtansine), approved for HER2-positive breast cancer, showed these side effects in pivotal trials like EMILIA and TH3RESA: nausea (up to 75% of patients), fatigue (65%), anemia (60%), diarrhea (45%), and low platelet counts (thrombocytopenia, 45%). Liver issues, including elevated enzymes (50%), were also frequent.[1][2]
Serious Adverse Events Under Close Monitoring
Trials tracked severe risks like heart dysfunction (3-5% cardiac events), lung problems (interstitial lung disease/pneumonitis in 1-2%), and infusion reactions (up to 40%, mostly mild). Peripheral neuropathy occurred in 20-25%, with monitoring for worsening nerve damage. Infusion-related deaths were rare (0.5%).[1][2]
Why These Are Monitored Long-Term
Post-approval studies (e.g., KATHERINE trial) continue watching for delayed effects like secondary cancers, fertility impacts, and cumulative liver/heart toxicity, especially in combo regimens. Patients with liver disease or prior heart issues get extra checks via echocardiograms and blood tests.[2][3]
Differences Across Trials and Patient Groups
EMILIA (advanced cancer) had higher nausea/diarrhea rates than KATHERINE (adjuvant setting), where thrombocytopenia dropped to 30%. Older patients or those with metastases reported more fatigue and neuropathy. Trials excluded severe liver cases, but real-world monitoring flags higher risks there.[2]
How Side Effects Compare to Herceptin
Kadcyla adds chemotherapy (emtansine), worsening blood/platelet issues and liver toxicity over Herceptin alone (which mainly causes heart/infusion problems). Trials showed Kadcyla's overall severe event rate at 40% vs. 30% for Herceptin combos.[1]
[1]: FDA Label for Kadcyla
[2]: KATHERINE Trial (NEJM, 2019)
[3]: ClinicalTrials.gov - Kadcyla Studies